Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pfizer Inc. (PFE) has ended its Phase 1 trial NCT06704724, titled “A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS.” The study aimed to test an oral KRAS inhibitor in people with advanced lung, colorectal, and pancreatic cancers, focusing on safety, dosing, and early signs of benefit.
The main treatment was PF-07985045, a pill designed to block KRAS, a key driver in many hard-to-treat tumors. It was tested alone and with standard cancer drugs such as gemcitabine, nab-paclitaxel, cetuximab, FOLFOX regimens, immunotherapies like pembrolizumab, and another Pfizer asset, PF-07284892.
This was an interventional Phase 1 study with no randomization and no placebo group. Everyone knew what they were receiving, and the main goal was treatment, meaning the focus was on safety and how the drug behaved in the body rather than on direct comparison with existing options.
The trial was first submitted in late 2024, with participants expected to stay on study treatment for up to two years and be followed for up to four years in total. The latest update was posted on May 19, 2026, when the status changed to terminated, signaling that enrollment and dosing have stopped even though follow-up and data work can continue.
For investors, the termination of this early KRAS program is a clear negative data point for Pfizer’s oncology pipeline and may weigh modestly on sentiment around PFE’s high-risk, high-reward cancer bets. However, KRAS remains a crowded and strategic field, with players like Amgen and Mirati (Bristol Myers) pushing ahead, so the impact is more about pipeline mix and capital allocation than a broad hit to Pfizer’s long-term story.
The study has been updated and is no longer enrolling, and further details are available on the ClinicalTrials portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.